AR063559A1 - Compuesto de tetrahidrociclopenta [b] indol, su uso para la manufactura de un medicamento y composicion farmaceutica que lo comprende - Google Patents
Compuesto de tetrahidrociclopenta [b] indol, su uso para la manufactura de un medicamento y composicion farmaceutica que lo comprendeInfo
- Publication number
- AR063559A1 AR063559A1 ARP070104913A ARP070104913A AR063559A1 AR 063559 A1 AR063559 A1 AR 063559A1 AR P070104913 A ARP070104913 A AR P070104913A AR P070104913 A ARP070104913 A AR P070104913A AR 063559 A1 AR063559 A1 AR 063559A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- manufacture
- nrarb
- cyclopropyl
- reduction
- Prior art date
Links
- 238000004519 manufacturing process Methods 0.000 title abstract 2
- SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 title 1
- 239000002131 composite material Substances 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 abstract 3
- -1 Tetrahydrocyclopenta [b] indole compound Chemical class 0.000 abstract 3
- 229910003827 NRaRb Inorganic materials 0.000 abstract 2
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 abstract 2
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 abstract 1
- 206010002942 Apathy Diseases 0.000 abstract 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical group [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 abstract 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical group [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 abstract 1
- 208000010228 Erectile Dysfunction Diseases 0.000 abstract 1
- 206010057671 Female sexual dysfunction Diseases 0.000 abstract 1
- 206010058359 Hypogonadism Diseases 0.000 abstract 1
- 206010057672 Male sexual dysfunction Diseases 0.000 abstract 1
- 208000029725 Metabolic bone disease Diseases 0.000 abstract 1
- 206010049088 Osteopenia Diseases 0.000 abstract 1
- 208000001132 Osteoporosis Diseases 0.000 abstract 1
- 208000007502 anemia Diseases 0.000 abstract 1
- 210000000988 bone and bone Anatomy 0.000 abstract 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Chemical group BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 abstract 1
- 229910052794 bromium Inorganic materials 0.000 abstract 1
- 229910052799 carbon Inorganic materials 0.000 abstract 1
- 229910052801 chlorine Inorganic materials 0.000 abstract 1
- 239000000460 chlorine Chemical group 0.000 abstract 1
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 abstract 1
- 125000001153 fluoro group Chemical group F* 0.000 abstract 1
- 230000008717 functional decline Effects 0.000 abstract 1
- 125000001072 heteroaryl group Chemical group 0.000 abstract 1
- 201000001881 impotence Diseases 0.000 abstract 1
- 125000001786 isothiazolyl group Chemical group 0.000 abstract 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 abstract 1
- 210000003205 muscle Anatomy 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 125000003373 pyrazinyl group Chemical group 0.000 abstract 1
- 125000002098 pyridazinyl group Chemical group 0.000 abstract 1
- 125000004076 pyridyl group Chemical group 0.000 abstract 1
- 125000000714 pyrimidinyl group Chemical group 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 208000001076 sarcopenia Diseases 0.000 abstract 1
- 125000001424 substituent group Chemical group 0.000 abstract 1
- 125000001113 thiadiazolyl group Chemical group 0.000 abstract 1
- 125000000335 thiazolyl group Chemical group 0.000 abstract 1
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 abstract 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/56—Ring systems containing three or more rings
- C07D209/58—[b]- or [c]-condensed
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/56—Ring systems containing three or more rings
- C07D209/58—[b]- or [c]-condensed
- C07D209/70—[b]- or [c]-condensed containing carbocyclic rings other than six-membered
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Endocrinology (AREA)
- Cardiology (AREA)
- Diabetes (AREA)
- Neurology (AREA)
- Epidemiology (AREA)
- Reproductive Health (AREA)
- Heart & Thoracic Surgery (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Psychiatry (AREA)
- Immunology (AREA)
- Pain & Pain Management (AREA)
- Anesthesiology (AREA)
- Hospice & Palliative Care (AREA)
- Vascular Medicine (AREA)
- Pulmonology (AREA)
- Hematology (AREA)
- Gynecology & Obstetrics (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Indole Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US86648406P | 2006-11-20 | 2006-11-20 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR063559A1 true AR063559A1 (es) | 2009-02-04 |
Family
ID=39415431
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP070104913A AR063559A1 (es) | 2006-11-20 | 2007-11-05 | Compuesto de tetrahidrociclopenta [b] indol, su uso para la manufactura de un medicamento y composicion farmaceutica que lo comprende |
Country Status (36)
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2488990T3 (es) | 2008-02-22 | 2014-09-01 | Radius Health, Inc. | Moduladores selectivos del receptor de andrógenos |
| US8268872B2 (en) | 2008-02-22 | 2012-09-18 | Radius Health, Inc. | Selective androgen receptor modulators |
| SI2297100T1 (sl) * | 2008-05-16 | 2013-02-28 | Eli Lilly & Company | Tetrahidrociklopenta(b)indoli kot modulatorji androgenskega receptorja |
| AR078862A1 (es) | 2009-11-13 | 2011-12-07 | Lilly Co Eli | Ester isopropilico del acido ((s)-7-ciano-4-((2r,3s)-3-hidroxitetrahidrofuran-2-ilmetil)-1,2,3,4-tetrahidro-ciclopenta(b)indol-2-il)carbamico, composiciones farmaceuticas que lo comprenden y su uso en terapia |
| AU2011212813B2 (en) | 2010-02-04 | 2014-10-23 | Radius Health, Inc. | Selective androgen receptor modulators |
| DK2568806T3 (en) | 2010-05-12 | 2016-08-15 | Radius Health Inc | therapy Programs |
| US8642632B2 (en) | 2010-07-02 | 2014-02-04 | Radius Health, Inc. | Selective androgen receptor modulators |
| WO2012047617A1 (en) | 2010-09-28 | 2012-04-12 | Radius Health, Inc. | Selective androgen receptor modulators |
| US20140113824A1 (en) | 2011-05-10 | 2014-04-24 | Bayer Intellectual Property Gmbh | Bicyclic (thio)carbonylamidines |
| CN103265479B (zh) * | 2013-06-14 | 2017-12-08 | 南开大学 | 一种6‑氯甲基烟酸叔丁酯的合成方法 |
| PL3122426T3 (pl) | 2014-03-28 | 2023-05-15 | Duke University | Leczenie raka sutka z zastosowaniem selektywnych modulatorów receptora estrogenowego |
| US9421264B2 (en) | 2014-03-28 | 2016-08-23 | Duke University | Method of treating cancer using selective estrogen receptor modulators |
| TWI744723B (zh) | 2014-06-20 | 2021-11-01 | 美商基利科學股份有限公司 | 多環型胺甲醯基吡啶酮化合物之合成 |
| JOP20180072A1 (ar) * | 2014-09-11 | 2019-01-30 | Lilly Co Eli | علاج الأعراض المرتبطة بالعلاج بالحرمان من الأندروجين |
| HRP20220619T1 (hr) | 2016-06-22 | 2023-02-03 | Ellipses Pharma Ltd | Postupci za liječenje ar+ raka dojke |
| US20180185347A1 (en) | 2016-11-16 | 2018-07-05 | Transition Therapeutics (Ireland 2) Limited | Tetrahydrocyclopenta[b]indole compounds and phosphodiesterase inhibitors for the treatment of the signs and symptoms of bhp |
| EP3565542B1 (en) | 2017-01-05 | 2024-04-10 | Radius Pharmaceuticals, Inc. | Polymorphic forms of rad1901-2hcl |
| SG11202013177WA (en) | 2018-07-04 | 2021-01-28 | Radius Pharmaceuticals Inc | Polymorphic forms of rad 1901-2hcl |
| MA54946A (fr) | 2019-02-12 | 2021-12-22 | Radius Pharmaceuticals Inc | Procédés et composés |
| AU2021213297A1 (en) * | 2020-01-27 | 2022-08-18 | Eirgen Pharma Ltd. | Tetrahydrocyclopenta[b]indole compounds for the treatment of renal disease |
| US11986461B1 (en) * | 2023-08-24 | 2024-05-21 | King Faisal University | 3-(1-(3-(dimethylamino)propyl)-4,5-diphenyl-1H-imidazol-2-yl)pyridin-2-ol as an antitumor and antimicrobial compound |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4988820A (en) | 1986-02-21 | 1991-01-29 | Bayer Aktiengesellschaft | Cycloalkano(1,2-B) indole-sulponamides |
| GB8924392D0 (en) | 1989-10-30 | 1989-12-20 | Bayer Ag | Substituted cycloalkano/b/dihydroindole-and-indolesulphonamides |
| GB9008108D0 (en) | 1990-04-10 | 1990-06-06 | Bayer Ag | Cycloalkano(b)dihydroindoles and-indolesulphonamides substituted by heterocycles |
| DE4027278A1 (de) | 1990-08-29 | 1992-03-05 | Bayer Ag | Heterocyclisch substituierte indolsulfonamide |
| DE4131346A1 (de) | 1991-09-20 | 1993-03-25 | Bayer Ag | Indolsulfonamid substituierte dihydropyridine, verfahren zu ihrer herstellung und ihre verwendung in arzneimitteln |
| AU7558900A (en) * | 1999-10-14 | 2001-04-23 | Kaken Pharmaceutical Co., Ltd. | Tetrahydroquinoline derivatives |
| EP1423366A1 (en) | 2001-08-09 | 2004-06-02 | Eli Lilly And Company | Cyclopenta b ! indole derivatives as spla2 inhibitors |
| DE10164564B4 (de) | 2001-12-14 | 2007-05-16 | Zentaris Gmbh | Tetrahydrocarbazolderivate als Liganden für G-Protein gekoppelte Rezeptoren (GPCR) |
| JP4484108B2 (ja) | 2002-05-16 | 2010-06-16 | 塩野義製薬株式会社 | Ｐｇｄ２受容体拮抗作用を有する化合物 |
| US20060074124A1 (en) | 2003-09-12 | 2006-04-06 | Andrew Napper | Methods of treating a disorder |
| US20050245540A1 (en) * | 2003-12-09 | 2005-11-03 | Fujisawa Pharmaceutical Co., Ltd. | New methods |
| US7019022B2 (en) | 2003-12-15 | 2006-03-28 | Merck Frosst Canada & Co. | Substituted tetrahydrocarbazole and cyclopentanoindole derivatives |
| BRPI0507657A (pt) * | 2004-03-03 | 2007-07-10 | Lilly Co Eli | composto ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, método para tratar um distúrbio, e, uso de um composto ou um sal farmaceuticamente aceitável do mesmo |
| US20090170923A1 (en) * | 2004-11-22 | 2009-07-02 | Kristjan Gudmundsson | Hcv inhibitors |
| EP1817025A2 (en) | 2004-11-23 | 2007-08-15 | PTC Therapeutics, Inc. | Tetrahydrocarbazoles as active agents for inhibiting vegf production by translational control |
| US7297704B2 (en) | 2005-02-17 | 2007-11-20 | Wyeth | Cycloalkyfused indole, benzothiophene, benzofuran and idene derivatives |
| ES2339480T3 (es) | 2005-06-24 | 2010-05-20 | Eli Lilly And Company | Derivados de tetrahidrocarbazol utiles como moduladores del receptor de androgenos (sarm). |
| US20090022694A1 (en) | 2005-10-18 | 2009-01-22 | Distefano Peter | Sirt1 inhibition |
| WO2008019825A1 (en) | 2006-08-14 | 2008-02-21 | Santhera Pharmaceuticals (Schweiz) Ag | Use of tricyclic indole derivatives for the treatment of muscular diseases |
| SI2297100T1 (sl) | 2008-05-16 | 2013-02-28 | Eli Lilly & Company | Tetrahidrociklopenta(b)indoli kot modulatorji androgenskega receptorja |
-
2007
- 2007-06-11 UA UAA200904819A patent/UA98777C2/ru unknown
- 2007-11-02 TW TW096141527A patent/TWI398438B/zh not_active IP Right Cessation
- 2007-11-05 CL CL200703182A patent/CL2007003182A1/es unknown
- 2007-11-05 AR ARP070104913A patent/AR063559A1/es active IP Right Grant
- 2007-11-06 MY MYPI20092021A patent/MY154547A/en unknown
- 2007-11-06 HR HR20120032T patent/HRP20120032T1/hr unknown
- 2007-11-06 PL PL07844898T patent/PL2094658T3/pl unknown
- 2007-11-06 JP JP2009537272A patent/JP5399259B2/ja active Active
- 2007-11-06 AT AT07844898T patent/ATE538091T1/de active
- 2007-11-06 EA EA200970500A patent/EA015627B1/ru unknown
- 2007-11-06 RS RS20120056A patent/RS52191B/sr unknown
- 2007-11-06 SI SI200730864T patent/SI2094658T1/sl unknown
- 2007-11-06 AU AU2007324046A patent/AU2007324046B2/en active Active
- 2007-11-06 PT PT07844898T patent/PT2094658E/pt unknown
- 2007-11-06 KR KR1020097010232A patent/KR101121471B1/ko active Active
- 2007-11-06 US US12/447,693 patent/US7968587B2/en active Active
- 2007-11-06 CA CA2670340A patent/CA2670340C/en active Active
- 2007-11-06 NZ NZ576296A patent/NZ576296A/en not_active IP Right Cessation
- 2007-11-06 WO PCT/US2007/083745 patent/WO2008063867A2/en not_active Ceased
- 2007-11-06 CN CN2007800430385A patent/CN101541749B/zh active Active
- 2007-11-06 ES ES07844898T patent/ES2376048T3/es active Active
- 2007-11-06 BR BRPI0719092A patent/BRPI0719092B8/pt active IP Right Grant
- 2007-11-06 DK DK07844898.2T patent/DK2094658T3/da active
- 2007-11-06 MX MX2009005251A patent/MX2009005251A/es active IP Right Grant
- 2007-11-06 EP EP07844898A patent/EP2094658B1/en active Active
- 2007-11-08 PE PE2007001544A patent/PE20081161A1/es active IP Right Grant
- 2007-11-11 JO JO2007470A patent/JO2800B1/en active
-
2009
- 2009-04-27 IL IL198410A patent/IL198410A/en active IP Right Grant
- 2009-05-05 ZA ZA200903096A patent/ZA200903096B/xx unknown
- 2009-05-15 TN TNP2009000189A patent/TN2009000189A1/fr unknown
- 2009-05-18 CO CO09050693A patent/CO6190513A2/es active IP Right Grant
- 2009-05-19 CR CR10802A patent/CR10802A/es unknown
- 2009-05-20 EC EC2009009350A patent/ECSP099350A/es unknown
- 2009-05-28 NO NO20092103A patent/NO342531B1/no unknown
- 2009-06-17 MA MA32013A patent/MA31072B1/fr unknown
-
2012
- 2012-02-14 CY CY20121100148T patent/CY1112284T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR063559A1 (es) | Compuesto de tetrahidrociclopenta [b] indol, su uso para la manufactura de un medicamento y composicion farmaceutica que lo comprende | |
| JP2010510231A5 (cg-RX-API-DMAC7.html) | ||
| CA2608301C (en) | Pyrido[2,3-d]pyrimidines useful as hcv inhibitors, and methods for the preparation thereof | |
| CY1108690T1 (el) | Υποκατεστημενες ν-αρυλοπυρρολιδινες ως επιλεκτικοι διαμορφωτες υποδοχεα ανδρογονων | |
| EA200800781A1 (ru) | АМИДНЫЕ И КАРБАМАТНЫЕ ПРОИЗВОДНЫЕ АЛКИЛЗАМЕЩЕННЫХ N-[4-(4-АМИНО-1Н-ИМИДАЗО[4,5-c]ХИНОЛИН-1-ИЛ)БУТИЛ]МЕТАНСУЛЬФОНАМИДОВ И СПОСОБЫ | |
| ATE457979T1 (de) | Als androgen-rezeptor-modulatoren verwendbare tetrahydrocarbazol-derivate | |
| JP2008540554A5 (cg-RX-API-DMAC7.html) | ||
| SG149828A1 (en) | Alkoxy substituted imidazoquinolines | |
| WO2006086633A3 (en) | Substituted fused [1,2]imidazo[4,5-c] ring compounds and methods | |
| SG149829A1 (en) | Pyrazolopyridines and analogs thereof | |
| WO2006074003A3 (en) | CHIRAL FUSED [1,2]IMIDAZO[4,5-c] RING COMPOUNDS | |
| EA038122B9 (ru) | Ингибитор поверхностного антигена вируса гепатита b | |
| WO2005009370A3 (en) | Beta-carboline compounds and analogues thereof and their use as mitogen-activated protein kinase-activated protein kinase-2 inhibitors | |
| JP2008546791A5 (cg-RX-API-DMAC7.html) | ||
| CL2007001870A1 (es) | Composicion farmaceutica de dosificacion solida que comprende valsartan, amlodipina, hidroclorotiazida y aditivos farmaceuticamente aceptables; procedimiento de preparacion; y uso para el tratamiento de hipertension, insuficiencia cardiaca, infarto d | |
| RU2009120992A (ru) | Применение 3-андростандиола, необязательно в сочетании с агонистом 5-ht1а для лечения сексуальной дисфункции | |
| WO2007146124A3 (en) | Deuterated tadalafil derivatives | |
| EA200501326A1 (ru) | Пиримидины и триазины, ингибирующие репликацию вич | |
| ECSP077402A (es) | Derivados de 2-amido-4-feniltiazol, su preparación y su aplicación en terapéutica | |
| GEP20105025B (en) | Pharmaceutical compositions for treatent of atherosclerosis and related conditions and use thereof for treatment of these diseases | |
| MX2013000001A (es) | Composición farmaceutica de liberacion prolongada y acción retardada que comprende dapoxetina para administaracion oral. | |
| CL2011001078A1 (es) | Compuestos derivados de espirodihidrotetraazabenzoazuleno; procedimiento de preparacion; composicion farmaceutica; y su uso para la prevencion o tratamiento de dismenorrea, disfuncion sexual, hipertension, cirrosis hepatica y esquizofrenia entre otras. | |
| NO20076219L (no) | Farmasoytisk formulering med apomorfin for bukkal administrering | |
| ECSP056115A (es) | ANTAGONISTAS DEL RECEPTOR A2a DE 2-ALQUINIL- Y 2-ALQUENIL-PIRAZOLO-[4,3-e]-1,2,4-TRIAZOLO-[1,5-c]-PIRIMIDINA ADENOSINA | |
| JP2015522033A5 (cg-RX-API-DMAC7.html) |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant, registration |